Page 106 - Read Online

Page 10 of 11 Tessari et al. J Cancer Metastasis Treat 2020;6:18 I http://dx.doi.org/10.20517/2394-4722.2020.32

28. Francis O, Han F, Adams JC. Molecular phylogeny of a RING E3 ubiquitin ligase, conserved in eukaryotic cells and dominated by
homologous components, the muskelin/RanBPM/CTLH complex. PLoS One 2013;8:e75217.
29. Tomastikova E, Cenklova V, Kohoutova L, Petrovska B, Vachova L, et al. Interactions of an arabidopsis RanBPM homologue with LisH-
CTLH domain proteins revealed high conservation of CTLH complexes in eukaryotes. BMC Plant Biol 2012;12:83.
30. Salemi LM, Maitland MER, McTavish CJ, Schild-Poulter C. Cell signalling pathway regulation by RanBPM: molecular insights and
disease implications. Open Biol 2017;7.
31. Lampert F, Stafa D, Goga A, Soste MV, Gilberto S, et al. The multi-subunit GID/CTLH E3 ubiquitin ligase promotes cell proliferation
and targets the transcription factor Hbp1 for degradation. Elife 2018;7.
32. Maitland MER, Onea G, Chiasson CA, Wang X, Ma J, et al. The mammalian CTLH complex is an E3 ubiquitin ligase that targets its
subunit muskelin for degradation. Sci Rep 2019;9:9864.
33. Qiao S, Langlois CR, Chrustowicz J, Sherpa D, Karayel O, et al. Interconversion between anticipatory and active GID E3 ubiquitin ligase
conformations via metabolically driven substrate receptor assembly. Mol Cell 2019; doi: 10.1016/j.molcel.2019.10.009.
34. Huffman N, Palmieri D, Coppola V. The CTLH complex in cancer cell plasticity. J Oncol 2019;2019:13.
35. Puverel S, Barrick C, Dolci S, Coppola V, Tessarollo L. RanBPM is essential for mouse spermatogenesis and oogenesis. Development
2011;138:2511-21.
36. Palavicini JP, Lloyd BN, Hayes CD, Bianchi E, Kang DE, et al. RanBP9 plays a critical role in neonatal brain development in mice. PLoS
One 2013;8:e66908.
37. Palavicini JP, Wang H, Bianchi E, Xu S, Rao JS, et al. RanBP9 aggravates synaptic damage in the mouse brain and is inversely correlated
to spinophilin levels in Alzheimer’s brain synaptosomes. Cell Death Dis 2013;4:e667.
38. Palavicini JP, Wang H, Minond D, Bianchi E, Xu S, et al. RanBP9 overexpression down-regulates phospho-cofilin, causes early synaptic
deficits and impaired learning, and accelerates accumulation of amyloid plaques in the mouse brain. J Alzheimers Dis 2014;39:727-40.
39. Wang R, Palavicini JP, Wang H, Maiti P, Bianchi E, et al. RanBP9 overexpression accelerates loss of dendritic spines in a mouse model of
Alzheimer’s disease. Neurobiol Dis 2014;69:169-79.
40. Atabakhsh E, Bryce DM, Lefebvre KJ, Schild-Poulter C. RanBPM has proapoptotic activities that regulate cell death pathways in
response to DNA damage. Mol Cancer Res 2009;7:1962-72.
41. Liu T, Roh SE, Woo JA, Ryu H, Kang DE. Cooperative role of RanBP9 and P73 in mitochondria-mediated apoptosis. Cell Death Dis
2013;4:e476.
42. Kramer S, Ozaki T, Miyazaki K, Kato C, Hanamoto T, et al. Protein stability and function of p73 are modulated by a physical interaction
with RanBPM in mammalian cultured cells. Oncogene 2005;24:938-44.
43. Suresh B, Ramakrishna S, Kim YS, Kim SM, Kim MS, et al. Stability and function of mammalian lethal giant larvae-1 oncoprotein are
regulated by the scaffolding protein RanBPM. J Biol Chem 2010;285:35340-9.
44. Shao S, Sun PH, Satherley LK, Gao X, Ji KE, et al. Reduced RanBPM expression is associated with distant metastasis in gastric cancer
and chemoresistance. Anticancer Res 2016;36:1295-303.
45. Qin C, Zhang Q, Wu G. RANBP9 suppresses tumor proliferation in colorectal cancer. Oncol Lett 2019;17:4409-16.
46. Yin YX, Sun ZP, Huang SH, Zhao L, Geng Z, et al. RanBPM contributes to TrkB signaling and regulates brain-derived neurotrophic
factor-induced neuronal morphogenesis and survival. J Neurochem 2010;114:110-21.
47. Wang D, Li Z, Schoen SR, Messing EM, Wu G. A novel MET-interacting protein shares high sequence similarity with RanBPM, but fails
to stimulate MET-induced Ras/Erk signaling. Biochem Biophys Res Commun 2004;313:320-6.
48. Yuan Y, Fu C, Chen H, Wang X, Deng W, et al. The Ran binding protein RanBPM interacts with TrkA receptor. Neurosci Lett
2006;407:26-31.
49. Cheng L, Lemmon S, Lemmon V. RanBPM is an L1-interacting protein that regulates L1-mediated mitogen-activated protein kinase
activation. J Neurochem 2005;94:1102-10.
50. Tessari A, Parbhoo K, Pawlikowski M, Fassan M, Rulli E, et al. RANBP9 affects cancer cells response to genotoxic stress and its
overexpression is associated with worse response to platinum in NSCLC patients. Oncogene 2018; doi: 10.1038/s41388-018-0424-8.
51. Zhao Z, Cheng S, Zabkiewicz C, Chen J, Zhang L, et al. Reduced expression of RanBPM is associated with poorer survival from lung
cancer and increased proliferation and invasion of lung cancer cells in vitro. Anticancer Res 2017;37:4389-97.
52. Zhu LL, Wang CH, Yang HP, Shu WH. Expression of cartilage antitumor component RanBP9 in osteosarcoma. J Biol Regul Homeost
Agents 2016;30:103-10.
53. Liu H, Ding J, Kohnlein K, Urban N, Ori A, et al. The GID ubiquitin ligase complex is a regulator of AMPK activity and organismal
lifespan. Autophagy 2019; doi: 10.1080/15548627.2019.1695399:1-17.
54. Bao J, Tang C, Li J, Zhang Y, Bhetwal BP, et al. RAN-binding protein 9 is involved in alternative splicing and is critical for male germ
cell development and male fertility. PLoS Genet 2014;10:e1004825.
55. Matsuoka S, Ballif BA, Smogorzewska A, McDonald ER 3rd, Hurov KE, et al. ATM and ATR substrate analysis reveals extensive protein
networks responsive to DNA damage. Science 2007;316:1160-6.
56. Palmieri D, Scarpa M, Tessari A, Uka R, Amari F, et al. Ran binding protein 9 (RanBP9) is a novel mediator of cellular DNA damage
response in lung cancer cells. Oncotarget 2016;7:18371-83.
57. DeWeirdt PC, Sanson KR, Hanna RE, Hegde M, Sangree AK, et al. Genetic screens in isogenic mammalian cell lines without single cell
cloning. bioRxiv 2019; doi: 10.1101/677385:677385.
58. Lord CJ, Ashworth A. BRCAness revisited. Nat Rev Cancer 2016;16:110-20.
59. Abbotts R, Topper MJ, Biondi C, Fontaine D, Goswami R, et al. DNA methyltransferase inhibitors induce a BRCAness phenotype that
sensitizes NSCLC to PARP inhibitor and ionizing radiation. Proc Natl Acad Sci U S A 2019;116:22609-18.
60. Pilie PG, Gay CM, Byers LA, O’Connor MJ, Yap TA. PARP inhibitors: extending benefit beyond BRCA-mutant cancers. Clin Cancer